Target the Prostacyclin Pathway With the First Oral Selective IP Receptor Agonist1
*REVEAL (Registry to Evaluate Early and Long-term PAH Disease Management) was a US-based, observational registry involving 55 academic and community-based treatment centers. 3515 patients enrolled between March 2006 and December 2009. Data based on therapy at time of enrollment. Population for this analysis was 2438 patients.2,3 REVEAL was funded and sponsored by Actelion Pharmaceuticals US, Inc.